
Benefits of Treating Hemophilia with Factor Concentrate
Also Available In: Japanese Treating people with hemophilia with safe, regulated plasma-derived factor concentrate directly reduces the social and economic
Year: 2016
Language: English
This resource is also available in: Arabic French Russian Spanish Simplified Chinese
Author(s): World Federation of Hemophilia
Format: Document
This illustrated schematic demonstrates the normal process of blood clotting, how it is diminished when a clotting factor is lacking, and how infusion of replacement therapy works to achieve normal levels of blood clotting. It also illustrates the clotting factor cascade and highlights the points in the cascade where each type of hemophilia treatment product acts to impact the ability to form blood clots.

Also Available In: Japanese Treating people with hemophilia with safe, regulated plasma-derived factor concentrate directly reduces the social and economic

Also Available In: Japanese This fact sheet demonstrates the benefits of providing basic treatment and care to people with hemophilia.

In this monograph, the author offers his perspective on the risk of infection from recombinant and plasma-derived products.

This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Russian A multifaceted

Small pool heat-treated intermediate purity concentrate may be the most suitable and cost-effective solution for some countries attempting sufficiency and

This monograph provides guidelines for the production of single-donor cryoprecipitate.